BPI Labs LLC, Largo, FL
Is BPI Labs LLC an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names BPI Labs LLC in Largo, FL, first registered Mar 4, 2019 and most recently registered Oct 14, 2026. FDA lists its last inspection as Apr 17, 2026, with a Form FDA 483 issued; FDA lists the action on that inspection as “Open”.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Largo, FL
- Initial registration
- Mar 4, 2019
- Most recent registration
- Oct 14, 2026
- Last inspection
- Apr 17, 2026
- Form 483 issued at last inspection
- Yes
- Recall after last inspection
- No
- Action on last inspection
- Open
- Intends to compound sterile drugs from bulk substances
- Yes
- Earlier inspections
- FDA notes that an earlier inspection led to a Form 483, warning letter or other action
FDA inspections and actions on record
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as BPI Labs, LLC, Largo, FL, a 503B facility, with 5 listed actions, including 3 Form 483s (2021 to 2026).
| Document | |||
|---|---|---|---|
| Apr 17, 2026 | Form 483 | 483 Issued 04/17/2026 | fda.gov |
| Jul 28, 2025 | FMD-145 letter | FMD-145 Letter Issued 07/28/2025 | Not linked by FDA |
| Feb 21, 2025 | Form 483 | 483 Issued 02/21/2025 | fda.gov |
| Sep 1, 2021 | FMD-145 letter | FMD-145 Letter Issued 09/01/2021 | Not linked by FDA |
| Apr 30, 2021 | Form 483 | 483 Issued 04/30/2021 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists BPI Labs, LLC, Largo, FL (FEI number 3015156709), matched to this page by exact name, city and state. It lists 2 inspections: 1 VAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Apr 23, 2025 | Voluntary Action Indicated (VAI) | Bioresearch Monitoring (Drugs) | 3015156709 | 1267652 |
| Feb 21, 2025 | No Action Indicated (NAI) | Drug Quality Assurance (Drugs) | 3015156709 | 1261584 |
Form 483s FDA has published for this site
- Apr 17, 2026: Form 483 to BPI Labs, LLC, published May 27, 2026. fda.gov
- Feb 21, 2025: Form 483 to BPI Labs, LLC, published Feb 28, 2025. fda.gov
- Apr 30, 2021: Form 483 to BPI Labs, LLC, published May 31, 2022. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 8 numbered observations in all, across 3 inspections ending Apr 30, 2021 to Apr 17, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Apr 6, 2026 to Apr 17, 2026: 4 observations
- Firm on the cover
- BPI Labs, LLC, 12393 Belcher Rd S Ste 450, Largo, FL 33773-3097
- FEI number
- 3015156709
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 555 Winderley Place, Suite 200 Maitland, FL 32751
- Matched to this page by
- FEI number on the cover; linked from actions page, 503B list, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Your outsourcing facility compounds drug products using bulk drug substances that cannot be used in compounding under section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because they (a) are not used to compound drug products that appear on the drug shortage list in effect under section 506E of the Act and (b) do not appear on a list developed by FDA of bulk drug substances for which there is a clinical need.
Specifically,
Your facility compounded human drug products using tirzepatide bulk drug substance.
Observation 2
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Specifically,
A. Your firm failed to conduct a media fill for all worst-case conditions on a <Redacted B4> basis, including but not limited to, vial size, fill volume, number of vials, and processing run speeds. For example, There is no assurance that your firm can aseptically produce sterile drug products within your facility.
i. Your firm failed to assess the processing run speed and fill volume for the <Redacted B4> <Redacted B4> (Line □ ) during a <Redacted B4> media fill to simulate true production conditions. On Line <Redacted B4>, your firm performed a media fill in April 2025 yielding <Redacted B4> vials, with a fill volume of <Redacted B4> in a <Redacted B4> vial, for a total filling run time of <Redacted B4> hours and <Redacted B4> minutes. ...
Observation 3
The written stability program for drug products does not include reliable, meaningful and specific test methods.
Specifically,
Your firm failed to establish and follow an adequate written testing program designed to assess impurities profiles for Pyridoxine Hydrochloride used in the Tirzepatide and Pyridoxine Hydrochloride Injection, as outlined in SOP IQC-002 Stability Program (Revision No. 5, effective 29 March 2023).
The drug strengths for Tirzepatide and Pyridoxine Hydrochloride Injection produced and released by your firm include the following:
Product Code
Drug Product Strength
Batches Released
Redacted B4 30 mg/3 ml and 30 mg/3 ml
(b) (4)
10 mg/mL and 10 mg/mL
60 mg/3 ml and 30 mg/3 ml
40 mg/4 mL and 40 mg/4 mL
40 mg/2 mL and 20 mg/2mL
20 mg/2mL and 20 mg/2 mL
68 mg/4 mL and 40 mg/4 mL
Observation 4
Written procedures are not established and followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
Specifically,
Your firm's major cleaning performed and <Redacted B4> the production of Testosterone Cypionate Injection, USP, drug products failed to include swabbing analysis to verify that the cleaning was adeguate prior to the start of subsequent production. For example, the <Redacted B4> <Redacted B4> Line <Redacted B4> was used to produce Testosterone Cypionate Injection, USP 2000 mg/10 mL Batch 18611001A (I150H001A) on 10/20/2025 and then underwent major cleaning on 10/23/2025, but no swab samples were collected and analyzed to verify removal of Testosterone residues before Line F was released for use in the production of Tirzepatide and Pyridoxine Hydrochloride Injection, 60 mgl3 ml (20 mg/ml) and 30 mg/3 ml (IO mg/ml) Batch I842H007B on I 0/24/2025. Without analytical verification of cleaning effectiveness, there is no assurance that residues from Testosterone Cypionate Injection, USP has been adequately removed to prevent cross-contamination of subsequent batches.
(!~/)J '.!L. ...
Inspection Feb 10, 2025 to Feb 21, 2025: 1 observation
- Firm on the cover
- BPI Labs LLC, 12393 Belcher Rd S Ste 450, Largo, FL 33773-3097
- FEI number
- 3015156709
- Establishment type on the cover
- Outsourcing Facility / Sterile Drug Manufacturing Facility
- FDA district office on the cover
- 555 Winderley Place, Suite 200Maitland, FL 32751
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Specifically,
1 the following information is not found on your drug product labels:
•the statement "Office Use Only."
Examples of your drug product labels that do not contain this information, include but a re not limited to:
•Semaglutide Injection 1mg/mL, imL vial •Semaglutide Injection 5mg/2mL, 2mL vial •Semaglutide Injection 12.5mg/2.5mL, 2.5mL vial •Semaglutide Injection 2.5mg/mL, 1mL vial •Semaglutide Injection, 30mg/6mL, 6mL vial •Tirzepatide Injection, 30mg/3mL, 3mL vial •Tirzepatide Injection, 10mg/mL, 1mL vial •Tirzepatide Injection, 60mg/3mL vial ...
Inspection Apr 19, 2021 to Apr 30, 2021: 3 observations
- Firm on the cover
- BPI Labs LLC, 12393 Belcher Rd S Ste 450, Largo,FL 33773-3097
- FEI number
- 3015156709
- Establishment type on the cover
- Sterile Drug Manufacturer and 503B Outsourcing Facility
- FDA district office on the cover
- 555 Winderley Place, Suite 200 Maitland, FL 32 751
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
Specifically, during inspection, it was observed that the equipment <Redacted B4> and Labelling Machine type <Redacted B4> intended for labeling the pre-filled epinephrine syringes referenced in your NDA application has not been installed and qualified for use.
Observation 2
Potential suppliers were not evaluated and selected based on their ability to meet specified requirements.
Specifically, your firm was not evaluating suppliers based upon their ability to meet requirements establlshed in your Vendor Management System procedure (SOP IGN-034) and Purchasing System procedure (SOP IPC-001). Your firm's initial qualification (signed 02/26/2019) of your supplier of sterile 1 ml syringes indicates that a "review of collected data shows that the company has a vigorous quality system and capable of meeting customer expectations," but the approved supplier did not provide the information required per your firm's procedures and the questionnaire provided. For example, the initial Questionnaire far Customers provided by your supplier as a self-audit indicated that their Site Master File, manufacturing equipment, site maps and drawings, an explanation of how product is protected from the manufacturing environment, deviation handling procedures, previous deviations and 005 syringes, and an explanation of rejected batches of syringes within the last year were not provided. The supplier indicated that this information could be provided at the next on-site audit. ...
Observation 3
Risk analysis is inadequate.
Specifically, your firm's risk analysis conducted as part of the Combination Product Compliance 21 CFR Part 4 Drug and Device Constituent Ports document you identified as the design history file for your firm's 1 ml epinephrine syringe does not adequately identify the hazards, estimated risks, and mitigations associated with the use of your finished combination product.
For example, your firm identifies the glass syringe and rubber plunger components of your finished 1 ml epinephrine syringe as high risk for particulate matter, bacterial endotoxin, and lack of sterility in the Product Development Report for Epinephrine Injection, USP 1 mG/mL under section 2.1.3. In your firm's design history file your risk analysis conducted for the finished 1 ml epinephrine syringe device does not evaluate the risk levels for the eight risks identified by your firm. Additionally, one of the mitigations listed for risk of particulates is "incoming materials controls". Your firm's supplier control's do not adequately evaluate your supplier's capabilities of meeting the supplier requirements established by your firm, including technical and regulatory requirements. ...
GLP-1 records in this index
No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (BPI Labs LLC). That is not a finding beyond this index’s search.
The BPI Labs LLC pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
FDA NDC listings
FDA’s NDC Directory files, read Nov 15, 2026, list 14 products naming liraglutide, semaglutide and tirzepatide under the labeler name “BPI Labs LLC”, matched to this facility page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (14). The compounded product reports cover FDA reporting periods 2024-2 to 2026-1.
FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.
| Reporting periods | ||||||||
|---|---|---|---|---|---|---|---|---|
| 54288-846 | Liraglutide Injection, 18 mg/3 mL (6 mg/mL) | Liraglutide Injection, 18 mg/3 mL (6 mg/mL) | INJECTION | SUBCUTANEOUS | 18 mg/3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 | Compounded drugs |
| 54288-826 | Semaglutide Injection, 1 mg/mL | Semaglutide Injection, 1 mg/mL | INJECTION | SUBCUTANEOUS | 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 54288-827 | Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL) | Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL) | INJECTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 54288-831 | Semaglutide Injection, 12.5 mg/2.5 mL (5 mg/mL) | Semaglutide Injection, 12.5 mg/2.5 mL (5 mg/mL) | INJECTION | SUBCUTANEOUS | 12.5 mg/2.5 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 54288-833 | Semaglutide Injection, 2.5mg/mL (1mL vial) | Semaglutide Injection, 2.5mg/mL (1mL vial) | INJECTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 | Compounded drugs |
| 54288-832 | Tirzepatide Injection, 30 mg/3 mL | Tirzepatide Injection, 30 mg/3 mL | INJECTION | SUBCUTANEOUS | 10 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 54288-835 | Tirzepatide Injection, 10 mg/mL | Tirzepatide Injection, 10 mg/mL | INJECTION | SUBCUTANEOUS | 10 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 54288-836 | Tirzepatide Injection, 60 mg/3 mL | Tirzepatide Injection, 60 mg/3 mL | INJECTION | SUBCUTANEOUS | 20 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 54288-840 | Tirzepatide and Pyridoxine Hydrochloride Injection, 30 mg/3 mL (10 mg/mL) and 30 mg/3 mL (10 mg/mL) | Tirzepatide and Pyridoxine Hydrochloride Injection, 30 mg/3 mL (10 mg/mL) and 30 mg/3 mL (10 mg/mL) | INJECTION | SUBCUTANEOUS | 30 mg/3 mL; 30 mg/3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 | Compounded drugs |
| 54288-841 | Tirzepatide and Pyridoxine Hydrochloride Injection, 10 mg/mL and 10 mg/mL | Tirzepatide and Pyridoxine Hydrochloride Injection, 10 mg/mL and 10 mg/mL | INJECTION | SUBCUTANEOUS | 10 mg/1 mL; 10 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 | Compounded drugs |
| 54288-842 | Tirzepatide and Pyridoxine Hydrochloride Injection, 60 mg/3 mL (20 mg/mL) and 30 mg/3 mL (10 mg/mL) | Tirzepatide and Pyridoxine Hydrochloride Injection, 60 mg/3 mL (20 mg/mL) and 30 mg/3 mL (10 mg/mL) | INJECTION | SUBCUTANEOUS | 30 mg/3 mL; 60 mg/3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 | Compounded drugs |
| 54288-848 | Tirzepatide and Pyridoxine Hydrochloride Injection, 40 mg/4 mL (10 mg/mL) and 40 mg/4 mL (10 mg/mL) | Tirzepatide and Pyridoxine Hydrochloride Injection, 40 mg/4 mL (10 mg/mL) and 40 mg/4 mL (10 mg/mL) | INJECTION | SUBCUTANEOUS | 40 mg/4 mL; 40 mg/4 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 | Compounded drugs |
| 54288-859 | Tirzepatide and Pyridoxine Hydrochloride Injection, 20 mg/2 mL (10 mg/mL) and 20 mg/2 mL (10 mg/mL) | Tirzepatide and Pyridoxine Hydrochloride Injection, 20 mg/2 mL (10 mg/mL) and 20 mg/2 mL (10 mg/mL) | INJECTION | SUBCUTANEOUS | 20 mg/2 mL; 20 mg/2 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 | Compounded drugs |
| 54288-860 | Tirzepatide and Pyridoxine Hydrochloride Injection, 68 mg/4 mL (17 mg/mL) and 40 mg/4 mL (10 mg/mL) | Tirzepatide and Pyridoxine Hydrochloride Injection, 68 mg/4 mL (17 mg/mL) and 40 mg/4 mL (10 mg/mL) | INJECTION | SUBCUTANEOUS | 68 mg/4 mL; 40 mg/4 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2026-1 | Compounded drugs |
FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.
FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.